Vaccines

Adults 65 and older account for 70–85% of annual influenza-related deaths in the USA, underscoring the need for improved vaccine options, as current injectable vaccines show modest efficacy in many seasons.

The Centers for Disease Control and Prevention (CDC) and the National Foundation for Infectious Diseases (NFID) both weigh in on the evolving summer COVID-19 season, and strategies for prevention.

Matthew M Davis, MD, MAPP elaborates on how higher COVID-19 vaccination rates may curb the virus, alleviate childhood asthma symptoms, and protect against other common colds.

Despite initial concerns about vaccine safety, the study of nearly 3000 patients found no elevated risk of preterm birth associated with prenatal vaccination.

The $176 million award is for late-stage development of widespread immunization capability against H5 (avian) influenza, should such vaccines be needed.

Boosted neutralization against variant XBB15 fades within 3 months post-first booster in transplant recipients but improves with a second, hybrid immunity enhances, suggesting 3-6 month boost intervals for solid organ transplant recipients.

Novavax, Inc has unveiled promising results regarding its JN1 COVID-19 vaccine's efficacy against emerging virus variants, including KP2 and KP3.

Biopharmaceutical company, Dynavax, is comparing its investigational immunization against a FDA-approved vaccine.

The federal agency says everyone 75 years of age and older should receive the RSV vaccine.

Those individuals who received older versions of vaccines did not see significantly reduced risks of severe COVID-19 outcomes.

The state's attorney general filed the lawsuit against Pfizer for its ‘misleading statements’ about the vaccine.

A recently published secondary analysis sought to evaluate the risk of MACE in those patients who received one or two doses of the COVID-19 following acute coronary syndromes.

A study points to inpatients who were 50 years and older with the respiratory illness suffering from heart-related complications with the largest number of them having acute heart failure. 

The company announced data this morning for its investigational mRNA-1083 vaccine and plans to continue collecting data and working towards submitting a Biological License Application (BLA) for it.

Historically, pneumococcal vaccination in adults has been reserved for those at heightened risk, with adults bearing the cost compared to free childhood vaccinations.

The federal agency’s decision expands the vaccine’s eligibility to people 50 years of age and older, making it the first one for this age group.

Although there is a rise in the FLiRT family of mutations, the committee decided to seek protection against the older strain.

Ongoing surveillance from the CDC and FDA will continue to evaluate the risk of Guillan-Barré syndrome to guide further ACIP recommendations.

The company’s mRNA 1345 vaccine was given the nod by the federal agency and is indicated for seniors for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD).

CDC has been tracking New York City varicella outbreak among migrants with over 870 cases reported since October 2022.

Deaths varied greatly depending on the age group, with the oldest population having the highest rates.

This framework in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from animals to humans.

With 9 confirmed cases, recent incidences in schools and in the community, caregivers and individuals should stay informed if symptoms appear.

Recent study examines the relationship between COVID-19 vaccination and post-COVID conditions, shedding light on the potential long-term effects of vaccination.

Authorized for children in malaria-endemic regions, this vaccine aims to bridge the gap between demand and supply, offering hope against malaria's toll.

A study presented at The Annual Conference on Vaccinology Research (ACVR) offers insights into the efficacy of seasonal influenza vaccines.

The federal agency said that due to administrative constraints, they will not complete the review of mRNA-1345 by the PDUFA date of May 12.

Stating low demand, the company is removing their ChAdOx1-S [recombinant] (Vaxzevria) vaccine from the market.

Insights from the Annual Conference on Vaccinology Research (ACVR) on vaccine registries and assessing the safety of maternal and fetal health.

The investigational vaccine, mRNA-1345, developed for seniors has its FDA PDUFA date in a few days.